Brief: 3Sbio Says Phase Iii Clinical Study Of RHTPO Injection In Pediatric ITP Indication Achieved Pre-Defined Primary Endpoint
10/05/2022 16:03
May 10 (Reuters) - 3SBio Inc 1530.HK :
* PHASE III CLINICAL STUDY OF RHTPO INJECTION IN PEDIATRIC
ITP
INDICATION ACHIEVED PRE-DEFINED PRIMARY ENDPOINT
* PLANS TO SUBMIT NDA FOR RHTPO INJECTION TO NMPA IN NEAR
FUTURE
Source text for Eikon: ID:nHKS5KskVG
Further company coverage: 1530.HK